Roflumilast
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Trial Timeline
Nov 1, 2004 → Mar 1, 2007
NCT ID
NCT00242294About Roflumilast
Roflumilast is a phase 2/3 stage product being developed by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD). The current trial status is completed. This product is registered under clinical trial identifier NCT00242294. Target conditions include Chronic Obstructive Pulmonary Disease (COPD).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03381573 | Pre-clinical | Completed |
| NCT02068456 | Pre-clinical | Completed |
| NCT01354782 | Phase 1 | Completed |
| NCT01140542 | Phase 2 | Completed |
| NCT00246935 | Phase 3 | Completed |
| NCT00246922 | Phase 3 | Completed |
| NCT00242294 | Phase 2/3 | Completed |
| NCT00108823 | Phase 3 | Completed |
| NCT00242307 | Phase 2/3 | Completed |
| NCT00163475 | Phase 3 | Completed |
| NCT00076076 | Phase 3 | Completed |
| NCT00076089 | Phase 3 | Completed |
| NCT00073177 | Phase 3 | Completed |
| NCT00062582 | Phase 3 | Completed |
| NCT00163527 | Phase 3 | Completed |
| NCT00430729 | Phase 3 | Completed |
Competing Products
20 competing products in Chronic Obstructive Pulmonary Disease (COPD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |